CRSP:NASDAQ
Crispr Therapeutics AG
$42.24
arrow_downward
-0.89%(-0.38) 1D
Nob 13, 4:00:01 PM GMT-5 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa CRSP...
Buksan
$42.50
Mataas
$42.78
Mababa
$41.75
Mkt. cap
4.10B
Avg. na dami
1.64M
Dami
1.87M
Mataas nang 52-wk
$63.45
Mababa nang 52-wk
$41.75
EPS
-$4.75
Beta
1.49
Mga natitirang share
97.00M
Bilang ng mga empleyado
393
Buksan
$42.50
Mataas
$42.78
Mababa
$41.75
Mkt. cap
4.10B
Avg. na dami
1.64M
Dami
1.87M
Mataas nang 52-wk
$63.45
Mababa nang 52-wk
$41.75
EPS
-$4.75
Beta
1.49
Mga natitirang share
97.00M
Bilang ng mga empleyado
393
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Seeking Alpha
·
2 araw ang nakalipas
Crispr Therapeutics: More Patients, Same Losses (NASDAQ:CRSP)
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Tungkol sa Crispr Therapeutics AG
CEOSamarth Kulkarni
Mga Empleyado393
Itinatag2013
HeadquartersZug, Zug, Switzerland
SektorHealth Care
Industriya-
Websitecrisprtx.com